Rebecka Coles1, Evan D Kharasch. 1. Division of Clinical and Translational Research, Department of Anesthesiology, Washington University, St. Louis, Missouri 63110-1093, USA.
Abstract
PURPOSE: Hydroxylation of the antidepressant and smoking deterrent drug bupropion is a clinically important bioactivation and elimination pathway. Bupropion hydroxylation is catalyzed selectively by cytochrome P4502B6 (CYP2B6). CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion is chiral, used clinically as a racemate, and disposition is stereoselective. Nevertheless, it is unknown whether CYP2B6-catalyzed bupropion hydroxylation is stereoselective. METHODS: Hydroxylation of racemic bupropion by recombinant CYP2B6 and human liver microsomes was evaluated using a stereoselective assay. RESULTS: At therapeutic concentrations, hydroxylation of (S)-bupropion was threefold and 1.5-greater than (R)-bupropion, respectively, by recombinant CYP2B6 and human liver microsomes. In vitro intrinsic clearances were likewise different for bupropion enantiomers. CONCLUSIONS: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity.
PURPOSE: Hydroxylation of the antidepressant and smoking deterrent drug bupropion is a clinically important bioactivation and elimination pathway. Bupropion hydroxylation is catalyzed selectively by cytochrome P4502B6 (CYP2B6). CYP2B6-catalyzed bupropion hydroxylation has been used as an in vitro and in vivo phenotypic probe for CYP2B6 activity and CYP2B6 drug interactions. Bupropion is chiral, used clinically as a racemate, and disposition is stereoselective. Nevertheless, it is unknown whether CYP2B6-catalyzed bupropion hydroxylation is stereoselective. METHODS: Hydroxylation of racemic bupropion by recombinant CYP2B6 and human liver microsomes was evaluated using a stereoselective assay. RESULTS: At therapeutic concentrations, hydroxylation of (S)-bupropion was threefold and 1.5-greater than (R)-bupropion, respectively, by recombinant CYP2B6 and human liver microsomes. In vitro intrinsic clearances were likewise different for bupropion enantiomers. CONCLUSIONS: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity.
Authors: C L DeVane; S C Laizure; J T Stewart; B E Kolts; E G Ryerson; R L Miller; A A Lai Journal: J Clin Psychopharmacol Date: 1990-10 Impact factor: 3.153
Authors: L Gervot; B Rochat; J C Gautier; F Bohnenstengel; H Kroemer; V de Berardinis; H Martin; P Beaune; I de Waziers Journal: Pharmacogenetics Date: 1999-06
Authors: Leah M Hesse; Ping He; Soundararajan Krishnaswamy; Qin Hao; Kirk Hogan; Lisa L von Moltke; David J Greenblatt; Michael H Court Journal: Pharmacogenetics Date: 2004-04
Authors: M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin Journal: Mol Pharmacol Date: 2004-09 Impact factor: 4.436
Authors: Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2016-02-27 Impact factor: 3.205
Authors: Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta Journal: Drug Metab Dispos Date: 2016-01-22 Impact factor: 3.922
Authors: Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta Journal: J Pharmacol Exp Ther Date: 2016-06-02 Impact factor: 4.030